Exelon 4.6 mg/24 h and 9.5 mg/24 h Transdermal Patches
*Company:
Novartis Ireland LimitedStatus:
UpdatedLegal Category:
Product subject to medical prescription which may not be renewed (A)Active Ingredient(s):
*Additional information is available within the SPC or upon request to the company
Updated on 28 April 2025
File name
Exelon 4.6 mg24 h transdermal patch_PIL_11.04.2025_clean_Barcelona.pdf
Reasons for updating
- Change to section 4 - possible side effects
Updated on 21 January 2025
File name
Exelon transdermal patch_REGPIL_PF25-0013 12.2024_clean.pdf
Reasons for updating
- Change to section 4 - possible side effects
Updated on 21 January 2025
File name
Exelon transdermal patch_REGSPC_PF25-0013_12.2024_clean.pdf
Reasons for updating
- Change to section 4.8 - Undesirable effects
Legal category:Product subject to medical prescription which may not be renewed (A)
File name
Exelon Patient Diary RMP Educational Material Nov 2023.pdf
Reasons for updating
- Add New Doc
File name
Exelon Patient Diary RMP Educational Material Nov 2023.pdf
Reasons for updating
- Add New Doc
Updated on 26 May 2023
File name
Exelon-II-WS2442_REGPIL PF23-0102 Clean_14.04.2023.pdf
Reasons for updating
- Change to section 2 - what you need to know - warnings and precautions
Updated on 26 May 2023
File name
Exelon Patches_REG SPC_PF23-0102_14.04.2023_clean.pdf
Reasons for updating
- Change to section 4.4 - Special warnings and precautions for use
- Change to section 4.5 - Interaction with other medicinal products and other forms of interaction
Legal category:Product subject to medical prescription which may not be renewed (A)
File name
Exelon Patient Diary.pdf
Reasons for updating
- Add New Doc
Updated on 30 November 2021
File name
Exelon Patches REGPIL PF 21-0161_24-Jun-21_English_Clean.pdf
Reasons for updating
- Change to date of revision
Updated on 12 October 2020
File name
Exelon Patches PF 20-0088 BRAIN REGPIL April 2020_Clean.pdf
Reasons for updating
- Change to name of manufacturer
Updated on 10 December 2019
File name
Exelon Patches REGPIL PF 18-0110 April 2018 IPHA.pdf
Reasons for updating
- Improved presentation of PIL
Updated on 20 November 2019
File name
Exelon Patches REGSPC PF 19-0248 Oct 2019_Clean.pdf
Reasons for updating
- Change to section 6.5 - Nature and contents of container
- Change to section 8 - Marketing authorisation number(s)
Legal category:Product subject to medical prescription which may not be renewed (A)
Updated on 08 April 2019
File name
Exelon Patches REGSPC May 2018_IPHA.pdf
Reasons for updating
- File format updated to PDF
Legal category:Product subject to medical prescription which may not be renewed (A)
Updated on 20 September 2018
File name
Exelon Patches 6513945_R91_p1_LFT_X-4 RA reviewed 14.08.2018 IPHA.pdf
Reasons for updating
- New PIL for new product
Updated on 21 May 2018
File name
Exelon Patches REGSPC May 2018_Clean.docx
Reasons for updating
- Change to section 7 - Marketing authorisation holder
Legal category:Product subject to medical prescription which may not be renewed (A)
Free text change information supplied by the pharmaceutical company
Address change due to BREXIT
Updated on 06 March 2018
Reasons for updating
- New SPC for new product
Legal category:Product subject to medical prescription which may not be renewed (A)
Updated on 06 March 2018
Reasons for updating
- Improved presentation of SPC
- Change from individual to joint SPC
Legal category:Product subject to medical prescription which may not be renewed (A)
Free text change information supplied by the pharmaceutical company
Updated on 19 May 2016
Reasons for updating
- Change to warnings or special precautions for use
- Change of contraindications
- Change to MA holder contact details
Updated on 12 January 2016
Reasons for updating
- Change to warnings or special precautions for use
- Change to side-effects
Updated on 03 September 2015
Reasons for updating
- Change to MA holder contact details
Updated on 09 December 2014
Reasons for updating
- Change of manufacturer
Updated on 29 November 2013
Reasons for updating
- Change of manufacturer
Updated on 30 August 2013
Reasons for updating
- Change to warnings or special precautions for use
Updated on 31 August 2012
Reasons for updating
- Addition of joint PIL covering all presentations
Updated on 14 April 2009
Reasons for updating
- Change to drug interactions
- PIL retired pending re-submission
Updated on 06 November 2008
Reasons for updating
- Change to section 9 - Date of renewal of authorisation
- Joint SPC superseded by SPCs for individual presentations
Legal category:Product subject to medical prescription which may not be renewed (A)
Free text change information supplied by the pharmaceutical company
Updated on 21 October 2008
Reasons for updating
- Change to section 4.7 - Effects on ability to drive and use machines
- Change to section 4.5 - Interaction with other medicinal products and other forms of interaction
Legal category:Product subject to medical prescription which may not be renewed (A)
Free text change information supplied by the pharmaceutical company
Updated on 03 September 2008
Reasons for updating
- Change to section 4.5 - Interaction with other medicinal products and other forms of interaction
- Change to section 4.7 - Effects on ability to drive and use machines
- Change to section 10 - Date of revision of the text
Legal category:Product subject to medical prescription which may not be renewed (A)
Free text change information supplied by the pharmaceutical company
Updated on 14 May 2008
Reasons for updating
- New PIL for new product
Updated on 07 January 2008
Reasons for updating
- New SPC for new product
Legal category:Product subject to medical prescription which may not be renewed (A)
Novartis Ireland Limited
Address:
Vista Building, Elm Park Business Park, Merrion Road, Dublin 4, IrelandMedical Information E-mail:
medinfo.dublin@novartis.comTelephone:
+353 1 2601255Fax:
+353 1 2601263